Spanish industry association goes to court as Galicia breaks ranks on reimbursement
This article was originally published in Scrip
Farmaindustria, the Spanish R&D-based pharmaceutical industry, is appealing against a new law in Galicia, one of the 17 autonomous regions of Spain, that alters the list of medicines that the autonomous region reimburses. The association claims that the law will create a situation of uncertainty for the pharmaceutical industry.
You may also be interested in...
Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.
To maintain high prices and avoid access restrictions, companies marketing advanced therapies will have to show payers that their products save money elsewhere in the healthcare system.